Literature DB >> 16501212

Echocardiographic methods to select candidates for cardiac resynchronisation therapy.

Frank A Flachskampf1, Jens-Uwe Voigt.   

Abstract

Mesh：

Year:  2006        PMID： 16501212      PMCID： PMC1860843          DOI： 10.1136/hrt.2005.064014

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  19 in total

1.  Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation.

Authors:  Jeroen J Bax; Thomas H Marwick; Sander G Molhoek; Gabe B Bleeker; Lieselot van Erven; Eric Boersma; Paul Steendijk; Ernst E van der Wall; Martin J Schalij
Journal:  Am J Cardiol       Date:  2003-11-15       Impact factor: 2.778

2.  Usefulness of myocardial tissue Doppler echocardiography to evaluate left ventricular dyssynchrony before and after biventricular pacing in patients with idiopathic dilated cardiomyopathy.

Authors:  Jeroen J Bax; Sander G Molhoek; Lieselot van Erven; Paul J Voogd; Soeresh Somer; Eric Boersma; Paul Steendijk; Martin J Schalij; Ernst E Van der Wall
Journal:  Am J Cardiol       Date:  2003-01-01       Impact factor: 2.778

3.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

4.  Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure.

Authors:  Cheuk-Man Yu; Elaine Chau; John E Sanderson; Katherine Fan; Man-Oi Tang; Wing-Hong Fung; Hong Lin; Shun-Ling Kong; Yui-Ming Lam; Michael R S Hill; Chu-Pak Lau
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

5.  High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration.

Authors:  C-M Yu; H Lin; Q Zhang; J E Sanderson
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

6.  Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy.

Authors:  Cheuk-Man Yu; Gabe B Bleeker; Jeffrey Wing-Hong Fung; Martin J Schalij; Qing Zhang; Ernst E van der Wall; Yat-Sun Chan; Shun-Ling Kong; Jeroen J Bax
Journal:  Circulation       Date:  2005-09-06       Impact factor: 29.690

7.  Cardiac resynchronization therapy tailored by echocardiographic evaluation of ventricular asynchrony.

Authors:  Maria Vittoria Pitzalis; Massimo Iacoviello; Roberta Romito; Francesco Massari; Brian Rizzon; Giovanni Luzzi; Pietro Guida; Andrea Andriani; Filippo Mastropasqua; Paolo Rizzon
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

8.  Sequential versus simultaneous biventricular resynchronization for severe heart failure: evaluation by tissue Doppler imaging.

Authors:  Peter Sogaard; Henrik Egeblad; Anders K Pedersen; Won Yong Kim; Bent O Kristensen; Peter S Hansen; Peter T Mortensen
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

9.  Tissue Doppler imaging predicts improved systolic performance and reversed left ventricular remodeling during long-term cardiac resynchronization therapy.

Authors:  Peter Søgaard; Henrik Egeblad; W Yong Kim; Henrik K Jensen; Anders K Pedersen; Bent Ø Kristensen; Peter T Mortensen
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

10.  Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.

Authors:  Cheuk-Man Yu; Wing-Hong Fung; Hong Lin; Qing Zhang; John E Sanderson; Chu-Pak Lau
Journal:  Am J Cardiol       Date:  2003-03-15       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.